Kite Pharma announces positive results in patients with aggressive non-Hodgkin's lymphoma

(Burns McClellan) Kite Pharma Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy products for the treatment of cancer, today announced the publication of clinical results in a cohort of patients demonstrating the potential to treat aggressive non-Hodgkin's lymphoma with an anti-CD19 chimeric antigen receptor T cell therapy.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news